Paid Alzheimers Clinical Trials: Current Research Opportunities and Participation Details

Alzheimer's disease research has expanded substantially, with numerous clinical trials actively recruiting participants across multiple therapeutic approaches. This article provides an informational overview of paid and compensated Alzheimer's clinical trials currently enrolling in the United States, based on the latest research data available through trial registries and research institutions.

Overview of Active Alzheimer's Clinical Trials

As of 2025, the landscape of Alzheimer's disease clinical trials encompasses a diverse range of investigational therapies targeting different disease stages and pathological mechanisms. Active trials are recruiting participants at hundreds of sites nationwide, with enrollment deadlines extending into 2029 and 2035 1. These trials represent efforts by pharmaceutical companies, academic medical centers, and the National Institute on Aging to advance treatment options for mild cognitive impairment, mild dementia, moderate dementia, and early symptomatic Alzheimer's disease.

The therapeutic approaches under investigation vary widely. Some trials focus on monoclonal antibodies targeting amyloid beta accumulation, while others explore novel small-molecule compounds, immunomodulators, behavioral interventions, neuromodulation techniques, and combination therapies. Trials are also examining symptomatic treatments for behavioral complications such as agitation and psychosis, as well as preventive strategies for cognitively normal individuals at genetic risk 2. The geographic distribution of trial sites spans 17 to 24 states, with major recruiting centers in both urban and suburban locations.

Compensation Structure and Financial Participation Details

A critical distinction exists between 'paid trials' and 'compensated trials.' Most Alzheimer's disease clinical trials in the United States do not offer direct salary payments to participants but instead provide reimbursement for trial-related expenses such as travel, parking, meals, and lodging 3. Early-phase trials, particularly Phase I safety and tolerability studies, may offer modest stipends for time and inconvenience, provided such payments are reviewed and approved by an Institutional Review Board to ensure they are not coercive or undue inducements to enroll 4.

Participation in clinical trials is generally free of direct charge to participants. All study-related medical examinations, cognitive assessments, neuroimaging procedures (such as MRI, PET scans), biomarker testing, and investigational medications are covered by the trial sponsor, not the participant's insurance or out-of-pocket funds 5. However, participants should clarify directly with trial coordinators whether routine medical care costs for unrelated conditions, emergency room visits, or hospitalization unrelated to the trial protocol will be covered. The National Institute on Aging advises potential participants to ask trial coordinators specifically about 'subject reimbursement' or 'stipends' during the screening process to understand the exact financial structure of a particular trial 6.

Major Trial Categories and Investigational Therapies

Amyloid-targeted monoclonal antibodies represent one of the largest categories of active trials. Trials of donanemab (LY3002813) are recruiting at multiple sites nationwide, including studies evaluating its efficacy in early symptomatic Alzheimer's disease and real-world comparative effectiveness studies assessing outcomes versus standard care 1. Trontinemab trials are recruiting at 33 sites across 17 states for early symptomatic disease with an enrollment deadline of June 2028. Investigational compounds such as SNK01, LHP588, AMDX-2011P, and LY4006895 are also in active recruitment across varying disease stages.

Symptomatic treatment trials targeting behavioral and neuropsychiatric complications constitute another major category. Studies evaluating KarXT (xanomeline tartrate/trospium chloride) for agitation and cognitive impairment are recruiting at 25 sites across 16 states, with enrollment deadlines extending to February 2029. BMS-986368, a FAAH/MAGL inhibitor for agitation, is recruiting at 37 sites across 16 states. ITI-1284 for psychosis associated with Alzheimer's disease is recruiting at 27 sites across 6 states. These trials evaluate both safety and efficacy through standardized rating scales such as the Neuropsychiatric Inventory and cognitive assessments 1.

Eligibility Criteria and Participant Requirements

Eligibility criteria vary significantly across trials but share common features. Most trials require biomarker confirmation of Alzheimer's disease pathology, typically through amyloid positron emission tomography (PET) imaging, cerebrospinal fluid biomarkers (tau/amyloid ratios), or plasma biomarkers (phosphorylated tau variants and amyloid ratios) 1. Cognitive status is assessed using standardized instruments such as the Mini-Mental State Examination (MMSE) score, Montreal Cognitive Assessment (MoCA), or Clinical Dementia Rating (CDR) scale, with specific score cutoffs defining trial populations.

Age requirements typically range from 50 to 60 years and older, though some early-phase studies enroll healthy younger participants. Most trials mandate identification of a reliable study partner or caregiver who can provide written informed consent and participate in research visits. Vision and hearing acuity sufficient to complete neuropsychological testing (with corrective devices permitted) is required. Participants must be willing and able to undergo MRI scans, PET imaging or lumbar puncture for cerebrospinal fluid collection, and blood draws for biomarker analysis. Exclusion criteria often include significant cardiovascular disease, unstable medical conditions, current neurological disorders unrelated to Alzheimer's disease, and active malignancy 1.

Trial Duration, Visit Frequency, and Time Commitments

Clinical trial durations vary considerably depending on the investigational therapy and trial phase. Short-term studies, such as single-dose safety assessments, may require only a screening visit followed by a single treatment day and 24-hour follow-up visit. Longer-term trials typically span 1.5 to 2.5 years with 6 to 28 planned study visits distributed across the enrollment period 1. Extended observational studies and real-world comparative effectiveness trials may extend to nearly 5 years with quarterly or semi-annual assessments.

Individual visits generally require 2 to 4 hours, though initial screening visits and comprehensive biomarker assessment days may extend to 6 or more hours. Travel expectations vary by site; some local participants may have minimal travel burden, while others may travel significant distances for enrollment sites. Multiple study visits create cumulative time commitments that span months or years, requiring consistency and reliability from both participants and their caregivers. Transportation reimbursement, meal provisions at research sites, and parking compensation are standard offerings to offset logistical burdens 3.

Resources for Locating and Screening for Trial Eligibility

ClinicalTrials.gov remains the primary federal database for identifying active Alzheimer's disease clinical trials in the United States, allowing individuals to filter by disease stage, location, intervention type, and enrollment status 7. The Alzheimer's Association TrialMatch service offers a free, personalized clinical trial matching tool that collects health profile information and identifies trials for which individuals may be eligible based on their age, location, cognitive status, and biomarker findings 8. The National Institute on Aging provides educational resources explaining trial participation, what to expect, and questions to ask trial coordinators before enrollment.

Potential participants should be aware that screening itself requires time investment. Initial phone screenings may take 30 minutes to 1 hour, while in-person screening visits can require 4 to 8 hours and may include cognitive testing, medical history review, physical examination, blood work, and discussion of informed consent with study staff. Not all screened individuals will be deemed eligible; exclusion often occurs based on biomarker findings, cognitive performance outside the target range, significant medical comorbidities, or inability to identify a reliable study partner. Individuals should confirm that reimbursement for screening visit time and expenses is available before investing in an initial evaluation, as some trials do not reimburse failed screening visits 6.

Risks, Ethical Oversight, and Participant Protections

All clinical trials involving human participants are subject to federal ethical oversight through Institutional Review Boards (IRBs), which review protocols to ensure that benefits justify risks and that informed consent procedures are rigorous and transparent. However, participation in any clinical trial carries potential risks. These may include adverse effects from investigational medications (ranging from mild gastrointestinal upset to serious neurological events), imaging-related risks (such as claustrophobia during MRI), procedural complications (such as infection or bleeding from lumbar puncture), and unknown long-term effects of novel compounds 4.

Amyloid-related imaging abnormalities (ARIA), including amyloid-related imaging abnormalities-edema (ARIA-E) and amyloid-related imaging abnormalities-hemosiderin deposition (ARIA-H), represent specific risks associated with anti-amyloid monoclonal antibodies. These radiological findings may be asymptomatic or associated with cognitive decline, headaches, confusion, or vision changes. Participants must consent to regular brain MRI monitoring to detect these abnormalities. Regulatory requirements mandate that trial sponsors maintain ongoing safety monitoring and must halt trials or modify protocols if unacceptable safety signals emerge. Participants retain the right to withdraw from trials at any time without penalty or loss of access to standard medical care 5. Insurance coverage for routine medical care unrelated to the trial is protected under the Affordable Care Act, though the investigational intervention itself and trial-related procedures are sponsor-covered.

Sources

1. Paid Trials database containing 25+ active Alzheimer's disease clinical trials with site counts, enrollment deadlines, and inclusion/exclusion criteria as of 2025
2. National Institute on Aging Alzheimer's disease research program describing current therapeutic approaches and trial landscape
3. ClinicalTrials.gov and Alzheimer's Association TrialMatch documentation regarding compensation structures for clinical trial participants
4. U.S. Food and Drug Administration guidance on ethical considerations and institutional review board oversight of payment to research participants
5. Mayo Clinic and NIH guidelines on cost coverage and participant protections in clinical trials
6. National Institute on Aging participant education materials regarding trial screening, compensation, and informed consent procedures
7. ClinicalTrials.gov federal database of all registered clinical trials in the United States
8. Alzheimer's Association TrialMatch service and educational resources on trial participation